Stomach Cancer Clinical Trials

08/04/2025

Recruiting
Avutometinib and Defactinib in Diffuse Gastric Cancer

https://clinicaltrials.gov/study/NCT06487221

08/04/2025

Recruiting
Comparison of Outcomes of Multiple Platforms for Assisted Robotic Gastrectomy
https://clinicaltrials.gov/study/NCT06362070

01/28/2025

Global Genes recently released Early and Often: Reimagining patient community engagement to improve clinical trials feasibility.

The paper, authored by the Global Genes Corporate Alliance with input from the Global Genes’ Global Advocacy Alliance, argues drug developers can improve the time and cost of rare disease clinical trials through better engagement with the patient community to better inform discovery and development of therapies. This report shows that listening to patient communities isn’t just helpful—it’s transformational. Advocacy leaders and patients provide the qualitative insights that traditional data can’t capture, uncovering critical factors that drive clinical trial success. Your Role Is Essential.

Download Your Copy Today.

01/13/2025

Patient Webinar: Why Should I Consider a Clinical Trial?

Free NCCN patient webinar for those wanting to learn more about Clinical Trials.

10/23/2024

There is still time to register to attend in person or virtually for our Fall 2024 Spotlight on Stomach Cancer at the Penn Medicine - Abramson Cancer Center

Register today!

https://www.med.upenn.edu/stomach2024/

In Person or Virtually      Law Auditorium | Jordan Medical Education CenterPerelman Center for Advanced Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104

10/18/2024

You have been invited to participate in a new Interview Opportunity for Gastric Cancer Patients and Caregivers. If you qualify, you may be scheduled for a 60-minute online interview.

If you qualify to complete the interview, you will receive $120.

Please click here to start the survey today.

https://roi-rocket.org/?a=65895&c=73341&s1=nostomachforcancer

Survey Number: 64544

Thanks in advance for your participation. If you have any questions, please email the address below with the survey number.

rachel.cohen@roirocket.com

Please Note: This survey is for research purposes only. There will be no direct sales or promotions due to your participation. Your individual responses will be kept confidential, anonymous, and reported in aggregate.

06/04/2024

We are so proud and excited to have the ability to provide vital and necessary funding to one of the most talented and caring stomach cancer doctors at the National Institutes of Health (NIH). Dr. Jeremy Davis is considered to be a leading expert in the research and care of stomach cancer patients with sporadic and hereditary diseases.

This new grant will help support ongoing CDH1 family research efforts at the National Cancer Institute and could not have been possible without your financial support.

The check was presented to Dr. Davis at the National Institutes of Health (NIH) Inaugural Think Tank on Gastric Cancer Prevention.

05/28/2024

Third-Party Paid Market Research Study - Experiences with Stomach Cancer.

• Participation consists of a one-time, anonymous 90-minute online discussion with a researcher sharing experiences about your patient journey.
• Dates: June 6th-7th (various times available)
• Incentive: $250 paid within 1-2 weeks

All interested patients will take the appropriate pre-screening questionnaire to gauge eligibility. No treatments will be offered at this time, and they are not selling anything. The information gathered will remain confidential and used for research purposes only.

PATIENTS can apply here https://surveys.opinionslink.com/r/4PQnSM

04/22/2024

https://www.merck.ca/en/newsroom/health-canada-approves-keytruda-as-a-first-line-treatment/

KEYTRUDA (pembrolizumab) Injection 100 mg

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

04/09/2024

The cadonilimab combination showed improvement in overall survival, progression-free survival, duration of response and objective response.

02/21/2024

https://www.curetoday.com/view/first-patient-dosed-with-drug-combo-in-phase-2-gastric-cancer-trial

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.

02/09/2024

Costs of Cancer Prevention in CDH1 Variant Carriers- An ASCO Journal of Clinical Oncology Podcast featuring Board Member Kathryn Carr and Dr. Jeremy Davis from the National Cancer Institute

https://ascopubs.org/do/costs-cancer-prevention-cdh1-variant-carriers

Dr. Shannon Westin and her guests, Dr. Jeremy Davis and patient advocate Kathryn Carr, discuss the paper